Sniffer dogs detecting bladder (urothelial) cancer from urine
Official title: Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs
Run by University Hospital, Strasbourg, France · NCT07334314 · Data updated 2026-11-12
This study will test whether trained sniffer dogs can detect bladder cancer by smelling urine from adults scheduled for cystoscopy or other endourological procedures.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 340 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 2 sites (Colmar and 1 other locations) |
| Status | Recruiting |
| Started | June 20, 2025 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | January 12, 2026 |
| Trial ID | NCT07334314 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (over 18) scheduled for an initial cystoscopy or another endourological procedure who will have a routine urine sample taken in the month before the procedure.
✕Probably not a fit
Patients who are pregnant or breastfeeding, under guardianship, with recent other active cancers, or who cannot provide a routine urine sample (or who are not treated at the participating hospitals) are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects urine samples from adults scheduled for cystoscopy or related endourological procedures and presents anonymized samples to assistance dogs trained to detect cancer by smell. The primary aim is to estimate the sensitivity of canine olfactory detection for urothelial carcinoma compared with routine diagnostic findings from cystoscopy and pathology. Eligible participants are adults who will provide a urine sample as part of routine care; pregnant or breastfeeding women and those with recent other active cancers are excluded. No experimental treatments are given to patients — only urine samples are used for the canine detection testing.
Why it matters
Potential benefit: If successful, this approach could offer a noninvasive, low-cost way to help flag patients who may need faster diagnostic follow-up for bladder cancer.
How similar studies have gone: Prior small studies have shown that trained dogs can detect various cancers, including some promising results for bladder cancer in urine, but the evidence is limited and not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (\> 18 years old) * Subject scheduled for any endourological surgery involving an initial cystoscopy, the most common of which are: transurethral resection of the bladder, transurethral resection of the prostate, internal optical urethrotomy, bladder lithoclast, ureteral stent replacement, ureteroscopy, etc. (non-exhaustive list) * Subjects for whom a urine sample (for bacteriological or cytological testing) is planned as part of routine practice in the month prior to the procedure * Subjects affiliated with a health insurance plan or beneficiaries of such a plan Exclusion Criteria: * Absence of signed informed consent / inability to provide the subject with informed information (emergency situations, difficulties in understanding the subject, etc.) * Patient under guardianship, conservatorship, or judicial protection * History of cancer other than urothelial bladder carcinoma, unless in complete remission for \> 5 years * Pregnant or breastfeeding women
Where it's running
-
Hôpitaux Civils de Colmar
Colmar, France Recruiting -
Hôpitaux Universitaires de Strasbourg
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Victor GAILLARD
- Email: victor.gaillard@chru-strasbourg.fr
- Phone: +33 3 69 55 10 55
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Urothelial Carcinoma Biospecimen Collection and Data Study
This project tests collecting and storing tissue, blood, and imaging data from adults with urothelial carcinoma to support translational research.
-
DBC-664 in adults with solid tumors
A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.
-
First-in-human test of HH160 in people with advanced solid tumors
HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.
-
BMS-986504 combined with standard treatments for certain metastatic MTAP‑deleted solid tumors
This trial tests whether adding the experimental drug BMS‑986504 to standard cancer treatments is safe for people with advanced MTAP‑deleted mesothelioma, gastroesophageal, or urothelial cancers.
-
Trastuzumab plus serplulimab with chemotherapy for HER2-positive advanced biliary tract or urothelial cancer after prior therapy
This study will test whether adding trastuzumab and serplulimab to chemotherapy helps people with HER2-positive unresectable or metastatic biliary tract cancer or urothelial carcinoma who have not responded to standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.